Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439947 | 0.89 | CYP19A1 (0.52) | MAPTCYP19A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3617407 | 0.87 | CTSV (0.47) | MAPTCYP19A1KMT2AMEN1CTSV | |
| SCHEMBL3255840 | 0.80 | MAPT (0.56) | MAPTKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL3691078 | 0.79 | MAPT (0.55) | MAPTSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL13592956 | 0.78 | MAPT (0.54) | MAPTSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL8031386 | 0.77 | MAPT (0.56) | MAPTCYP19A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4404192 | 0.77 | MAPT (0.37) | MAPTKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL31261608 | 0.77 | SGMS2 (0.60) | KMT2AMEN1 | |
| SCHEMBL3255304 | 0.77 | CTSV (0.44) | MAPTCYP19A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30662860 | 0.75 | KMT2A (0.54) | CYP19A1KMT2AMEN1SMN1; SMN2CTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032563-B1 | BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON PLK | GLAXOSMITHKLINE LLC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-12-31 | — | — | US | disclosed |
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615643-B2 | 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2009-05-14 | — | — | US | disclosed |
| EP-2032564-A2 | SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | KUNTZ KEVIN | 2008-12-04 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| EP-1924572-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SmithKline Beecham Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007143506-A2 | SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007143506-A2 | SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326029-A1 | NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS | CYP3A4, CYP2C8, ABCB1 | MAPT 2133/4885CYP19A1 855/4885KMT2A 2951/4885 |
| US-20090124615-A9 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | MAPT 1126/4885CYP19A1 1755/4885KMT2A 2733/4885 |
| US-20080300247-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | MAPT 1126/4885CYP19A1 1755/4885KMT2A 2733/4885 |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | ABCB1, CYP3A5, CYP3A4 | MAPT 1151/4885CYP19A1 1722/4885KMT2A 1903/4885 |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | MAPT 2606/4885CYP19A1 183/4885KMT2A 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.